25.11.2024 13:01:14
|
Merck Reports Positive Topline Results From The Phase 3 ZENITH Study Evaluating WINREVAIR In PAH
(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH) functional class (FC) III or IV at high risk of mortality.
ZENITH met its primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality.
In the study, WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy.
Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive WINREVAIR through the SOTERIA open-label extension study.
WINREVAIR is currently approved in the U.S. and 36 countries based on the results from the Phase 3 STELLAR trial. Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.mehr Nachrichten
21.03.25 |
Schwacher Wochentag in New York: Dow Jones liegt am Freitagnachmittag im Minus (finanzen.at) | |
21.03.25 |
NYSE-Handel Dow Jones am Mittag ohne Schwung (finanzen.at) | |
19.03.25 |
NYSE-Handel: Börsianer lassen Dow Jones schlussendlich steigen (finanzen.at) | |
18.03.25 |
Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Verlust hätte eine Merck-Investition von vor einem Jahr eingebracht (finanzen.at) | |
14.03.25 |
NYSE-Handel: Börsianer lassen Dow Jones steigen (finanzen.at) | |
14.03.25 |
Freundlicher Handel: Dow Jones zum Start des Freitagshandels auf grünem Terrain (finanzen.at) | |
13.03.25 |
Minuszeichen in New York: Dow Jones zum Handelsende schwächer (finanzen.at) | |
13.03.25 |
Schwacher Handel: Dow Jones am Donnerstagnachmittag in Rot (finanzen.at) |
Analysen zu Merck Co.mehr Analysen
Aktien in diesem Artikel
Merck Co. | 87,30 | 0,58% |
|